Navigating the Bridge to CAR-T: Conversations and Cases on Individualized Bridging Strategies

This program will provide clinicians with a comprehensive overview of chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma, including the latest data on US Food and Drug Administration-approved B-cell maturation antigen-targeting constructs, ciltacabtagene autoleucel and idecabtagene vicleucel. Participants will explore the challenges patients face during the CAR-T manufacturing process, including disease progression and risk of adverse events, and the critical role of bridging therapy in controlling disease and potentially improving post CAR-T outcomes. The program will review current evidence on bridging therapy and discuss strategies for optimizing bridging therapy selection on an individualized patient basis. Additionally, this activity will highlight outstanding gaps in the literature, practical considerations for integrating evolving best practices into clinical care, and expert perspectives on how to navigate these complexities to enhance outcomes for patients receiving CAR-T therapy.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

Enduring / On-demand
Credit · Up to 1 credit
Commercial Support

Released

Oct 31, 2025
Last day to claim credit

Nov 1, 2026 3 weeks left

Virtual Course (Foundations of Aesthetic Medicine)	C$749
In-Person Hands-On Training (Foundations of Aesthetic Medicine)	C$4,995

Navigating the Bridge to CAR-T: Conversations and Cases on Individualized Bridging Strategies

Related courses

More from AKH Inc., Advancing Knowledge in Healthcare